Respiratory syncytial virus (RSV) is a non-segmented, single-stranded, negative-sense RNA virus belonging to the Pneumoviridae family. It represents the leading cause of acute respiratory tract infections in children worldwide. Treatment of RSV infections is primarily supportive, including hydration and oxygen supplementation.

Respiratory syncytial virus (RSV) is a non-segmented, single-stranded, negative-sense RNA virus belonging to the Pneumoviridae family. It represents the leading cause of acute respiratory tract infections in children worldwide. Treatment of RSV infections is primarily supportive, including hydration and oxygen supplementation. To date, no vaccines are available and the only licensed passive immunoprophylaxis is palivizumab. Given is high cost, palivizumab is recomended only in high-risk infants, including those born preterm and those with hemodynamically significant congenital heart disease (CHD) and bronchopulmonary dysplasia (BPD). Nevertheless, many hospitalized RSV-infected children do not fully meet the criteria for immune prophylaxis. Thus, over the last decades efforts continued to develop new monoclonal antibodies with a potential better cost-effectiveness ratio compared to palivizumab.